1. Home
  2. NKX vs PHAR Comparison

NKX vs PHAR Comparison

Compare NKX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California AMT-Free Quality Municipal Income Fund

NKX

Nuveen California AMT-Free Quality Municipal Income Fund

HOLD

Current Price

$12.52

Market Cap

645.5M

Sector

Finance

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$16.62

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKX
PHAR
Founded
2002
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
645.5M
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NKX
PHAR
Price
$12.52
$16.62
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$38.00
AVG Volume (30 Days)
109.3K
22.5K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
4.37%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.00
Revenue
N/A
$362,274,000.00
Revenue This Year
N/A
$24.80
Revenue Next Year
N/A
$6.84
P/E Ratio
N/A
$2,946.57
Revenue Growth
N/A
26.78
52 Week Low
$9.78
$7.50
52 Week High
$12.00
$18.12

Technical Indicators

Market Signals
Indicator
NKX
PHAR
Relative Strength Index (RSI) 35.61 51.06
Support Level $12.43 $16.23
Resistance Level $12.80 $17.00
Average True Range (ATR) 0.06 0.75
MACD -0.03 -0.16
Stochastic Oscillator 24.32 36.44

Price Performance

Historical Comparison
NKX
PHAR

About NKX Nuveen California AMT-Free Quality Municipal Income Fund

Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: